An observational study in Vision Disorder, Stroke and Brain Injuries, sponsored by Charles University, Czech Republic. Enrolling by invitation at 1 site in Czechia. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Charles University, Czech Republic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Vision Disorders with a site in Czechia — 3 open to participants now, 3 under way, none of them phase 3. Vision Disorders · Czechia.
Among the 16 studies in Vision Disorders with a site in Czechia, this one is one of 2 that started in 2026, is the only observational one, and was the 16th registered.
361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.
Browse Vision Disorders studies →3 of the 16 studies in Vision Disorders with a site in Czechia are open now. Recruiting first, the newest first:
Charles University, Czech Republic · Sites in Czechia
Ages 18–85
University Hospital Hradec Kralove · Sites in Czechia
Ages 18–65
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 13
First in 2008; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is below the median of 126 across 97 observational studies indexed under Vision Disorders.
Median enrollment 450 across the 15 interventional studies, 108 across the 1 observational. Of the 13 that completed or were terminated, 13 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 5 most frequent:
Charles University, Czech Republic is the lead sponsor of 228 studies on the registry; 76 are open to participants now.
Charles University, Czech Republic has 2 studies filed under Vision Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Vision Disorders with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This cross-sectional observational study aims to characterize acquired visual impairment in adults with acquired brain injury and to examine the relationship between objectively identified visual impairment and self-reported functional visual performance.
A total of 108 adults with acquired brain injury, including stroke, traumatic brain injury, and brain tumor, will undergo a standardized visual assessment. Objective visual function will be evaluated across five predefined domains: visual acuity, contrast sensitivity, visual field, oculomotor function, and visual attention/scanning. Self-reported functional visual performance will be assessed using the Revised Self-Report Assessment of Functional Visual Performance (R-SRAFVP).
The study will determine the proportion of participants with objectively identified visual impairment and examine the association between the R-SRAFVP score and the number of objectively impaired visual domains. The distribution of impairment across the individual visual domains will also be described.
Visual impairment following acquired brain injury may involve multiple aspects of visual function, including visual acuity, contrast sensitivity, visual field, oculomotor function, and visual attention. The relationship between objectively identified visual impairment and an individual's self-reported functional visual performance following acquired brain injury remains clinically relevant to characterize.
This cross-sectional observational study will characterize objectively identified visual impairment and self-reported functional visual performance in 108 adults with acquired brain injury, including stroke, traumatic brain injury, and brain tumor.
Participants will be recruited consecutively from eligible patients receiving inpatient or outpatient neurological or rehabilitation care at participating clinical sites. Each participant will undergo a single standardized study assessment.
Objective visual function will be evaluated across five predefined domains: visual acuity, contrast sensitivity, visual field, oculomotor function, and visual attention/scanning. Each domain will be classified as impaired or not impaired according to prespecified study criteria based on the corresponding visual assessment measures. The number of objectively impaired visual domains will be summarized using a study-derived count ranging from 0 to 5. This count does not represent a standardized composite score of any individual visual assessment instrument.
Self-reported functional visual performance will be assessed using the 33-item Revised Self-Report Assessment of Functional Visual Performance (R-SRAFVP). The R-SRAFVP score will be calculated according to the scoring procedure of the current assessment, which accounts for items rated as not applicable. Higher item ratings indicate greater independence and less difficulty in vision-dependent activities of daily living.
The primary objectives are to determine the proportion of participants with objectively identified visual impairment and to examine the association between the R-SRAFVP score and the number of objectively impaired visual domains. The proportion of participants with impairment in each individual visual domain will additionally be described.
The study population will consist of adults with acquired brain injury receiving inpatient or outpatient rehabilitation and neurological care at multiple clinical sites in the Czech Republic. Participants will be recruited from patients referred for rehabilitation assessment and treatment at participating healthcare facilities. The study population will include individuals with stroke, traumatic brain injury, and brain tumors at different stages of recovery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with acquired brain injury, including stroke, traumatic brain injury, and brain tumor, undergoing a single standardized assessment of objective visual function and self-reported functional visual performance. Participants are not assigned to an intervention as part of this observational study.
Proportion of participants with objectively identified visual impairment
Proportion of participants with at least one objectively identified impairment across the five predefined visual domains: visual acuity, contrast sensitivity, visual field, oculomotor function, and visual attention/scanning. Each domain will be classified as impaired or not impaired according to prespecified study criteria based on the corresponding visual assessment measures. A participant will be classified as having objectively identified visual impairment if impairment is identified in at least one of the five domains. The outcome will be reported as the number and percentage of participants meeting this definition.
Time frame: Baseline (single assessment)
Association between R-SRAFVP score and number of objectively impaired visual domains
Association between self-reported functional visual performance assessed using the 33-item Revised Self-Report Assessment of Functional Visual Performance (R-SRAFVP) and the extent of objectively identified visual impairment. The R-SRAFVP score will be calculated according to the scoring procedure of the current assessment, which accounts for items rated as not applicable; higher item ratings indicate greater independence and less difficulty in vision-dependent activities of daily living. Objective visual impairment will be summarized as a study-derived count ranging from 0 to 5, representing the number of impaired domains among visual acuity, contrast sensitivity, visual field, oculomotor function, and visual attention/scanning. The association between the R-SRAFVP score and the number of objectively impaired visual domains will be evaluated.
Time frame: Baseline (single assessment)
Proportion of participants with objectively identified impairment in each visual domain
Proportion of participants with objectively identified impairment in each of the five predefined visual domains: visual acuity, contrast sensitivity, visual field, oculomotor function, and visual attention/scanning. Each domain will be classified as impaired or not impaired according to prespecified study criteria based on the corresponding visual assessment measures. Results will be reported separately for each domain as the number and percentage of participants classified as impaired.
Time frame: Baseline (single assessment)
Plan to share: No — Individual participant data are not planned to be made publicly available or shared with other researchers. Study results will be disseminated in aggregated and de-identified form through scientific publications and presentations. No individual participant data sharing plan has been established for this study.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charles University, Czech Republic →